T. Baumgart

C5a receptor (CD88) blockade protects against MPO-ANCA GN.

T. Schall, L. Gan, J. Jaén, 2014, Journal of the American Society of Nephrology : JASN.

CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice.

T. Schall, I. Charo, T. Sullivan, 2013, American journal of physiology. Renal physiology.

Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.

T. Schall, T. Sullivan, J. Jaén, 2013, Metabolism: clinical and experimental.

CCR 2 antagonist CCX 140-B provides renal and glycemic benefits in diabetic transgenic human CCR 2 knockin mice

T. Schall, I. Charo, T. Sullivan, 2013 .

Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complications.

T. Schall, I. Charo, Daniel M. Johnson, 2012, The Journal of pharmacology and experimental therapeutics.

Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study

T. Schall, I. Charo, Daniel M. Johnson, 2016, PloS one.

A conformationally-constrained MHC class II I-Ag7-derived peptide protects NOD mice from the development of diabetes.

N. Solvason, K. Lafferty, T. Baumgart, 1999, Journal of autoimmunity.

Characterization of CCX282-B, an Orally Bioavailable Antagonist of the CCR9 Chemokine Receptor, for Treatment of Inflammatory Bowel Disease

Yu Wang, T. Schall, J. Jaén, 2010, Journal of Pharmacology and Experimental Therapeutics.

Cc chemokine receptor 9 (ccr9) antagonist ameliorates experimental ileitis and colitis

T. Schall, W. Rubas, M. Howard, 2005 .